Sentences with phrase «hematopoietic development»

One postdoctoral position is available in the Human hematopoietic development and disease modeling unit, headed by Andrea Ditadi at SR - Tiget

As an extension to genetics projects, we now aim to identify and characterize in greater depth genes implicated in hematopoietic development in the EU FP7 - funded BLUEPRINT project, which will generate reference genomes and epigenomes of at least 100 specific blood cell types.

Not exact matches

Scientists at the Helmholtz Zentrum München and their partners at ETH Zurich and the Technical University of Munich (TUM) have now used it to determine the development of hematopoietic stem cells in advance.

«Deep Learning predicts hematopoietic stem cell development.»

We examine their original thymic development: selection on hematopoietic cells leading to the acquisition of an original differentiation program.

Discussion themes included: - stem cell heterogeneity - stem cell fate decisions - stem cells in regeneration & development - stem cells in disease & treatment - stem cell related bioengineering & biomaterial - theoretical stem cell biology - mathematical modelling with a focus (but no restriction) on neural stem cells, hematopoietic stem cells and diabetes.

In conclusion, p21 deficiency results in the spontaneous development of a variety of tumors of hematopoietic, endothelial, and epithelial origin.

The aorta - gonad - mesonephros (AGM) region in the aortic wall appears to be the most important source of new blood cells, and it has been found to contain numerous hematopoietic stem cells by day 11 of mouse embryonic development.

The lab will be focused on the identification of cellular and molecular events regulating hematopoietic cell fate decisions with emphasis on DC development.

This is in accordance with previous reports that decitabine and 5 - azacytidine produce a marked synergistic effect in combination with suberoylanilide hydroxamic acid and romidepsin in T - lymphoma cell lines by modulating cell cycle arrest and apoptosis.26, 27 As a mechanism of action, KMT2D mutations of B - lymphoma cells promote malignant outgrowth by perturbing methylation of H3K4 that affect the JAK - STAT, Toll - like receptor, or B - cell receptor pathway.28, 29 Here our study indicated that dual treatment with chidamide and decitabine enhanced the interaction of KMT2D with the transcription factor PU.1, thereby inactivating the H3K4me - associated signaling pathway MAPK, which is constitutively activated in T - cell lymphoma.13, 30,31 The transcription factor PU.1 is involved in the development of all hematopoietic lineages32 and regulates lymphoid cell growth and transformation.33 Aberrant PU.1 expression promotes acute myeloid leukemia and is related to the pathogenesis of multiple myeloma via the MAPK pathway.34, 35 On the other hand, PU.1 is also shown to interact with chromatin remodeler and DNA methyltransferease to control hematopoiesis and suppress leukemia.36 Our data thus suggested that the combined action of chidamide and decitabine may interfere with the differentiation and / or viability of PTCL - NOS through a PU.1 - dependent gene expression program.

Dual actions of Meis1 inhibit erythroid progenitor development and sustain general hematopoietic cell proliferation.

Moreover, ES cell differentiation in vitro recapitulates events that take place during early embryonic development including the formation of the three germ layers of ectoderm, mesoderm and endoderm, and the emergence of endothelial, hematopoietic, cardiac, neuronal and hepatic or pancreatic cells [8], [9].

In a similar manner, the induction of hematopoietic (cluster 20, day 3.5 +4 = E7.5) and cardiovascular - specific (cluster 12, 3.5 +5 = E8.5) genes follows the chronological order of the appearance of blood islands and the formation of the heart tube during embryonic development [50], [51].

Comutation of p53 was able to rescue the hematopoietic defects seen in the single mutants, but led to tumor development.

Although, remarkable progress has been made in the in vitro development of T cells from ES cells [6], [7], this has not been the case for other hematopoietic cell lineages.

The Workshop on Inherited Hematopoietic Malignancies will discuss the scientific advances in understanding the pathogenesis of cancer development in individuals and families with germline mutations and predisposition to bone marrow derived malignancies.